SMSbiotech has announced the initiation of its first-in-human phase 1 clinical trial for chronic obstructive pulmonary disease (COPD).
This marks the transition of years of research into clinical development, with the goal of delivering a transformative therapy for millions living with the debilitating lung condition.
The first dose of SMSbiotech’s novel therapeutic candidate was administered to the inaugural patient last month. The phase 1 study, “A study to investigate small mobile stem cells (SMS cells) in participants aged 39 to 69 years with chronic obstructive pulmonary disease,” will enrol 18 COPD patients. It is designed to evaluate the safety and preliminary efficacy of SMSbiotech’s small mobile stem (SMS) cells—a unique, healthy, adult blood-derived cell population discovered and named by SMSbiotech.
Unlike traditional treatments, SMS cells are designed to regenerate damaged lung tissue. The off-the-shelf, non-invasive therapy is administered directly to the lungs through a nebulizer. Preclinical studies demonstrated significant restoration of lung function in as little as 10 days. The study duration is expected to be 15 months.
“The initiation of our phase 1 trial for COPD is a profound moment for SMSbiotech and, more importantly, for the millions of patients yearning for better treatment options,” said Abdulkader Rahmo, president of SMSbiotech.
“We are also encouraged to report that the first two sentinel patients have been dosed, initial safety data has been received, and the trial can now move forward—an important validation step as we continue this study. We are immensely optimistic about the potential of our small mobile stem cell therapy to not only manage COPD symptoms but to fundamentally alter the disease’s progression and potentially reverse its devastating effects. We believe this represents a new dawn for respiratory medicine, offering the promise of a future where patients can breathe easier and live fuller lives.”
The trial received regulatory approval from the Therapeutic Goods Administration (TGA), Australia’s regulatory authority equivalent to the U.S. Food and Drug Administration (FDA).
SMSbiotech has filed 16 patents and received seven granted patents for its technology. Pending sufficient safety data from this trial, the company plans to evaluate compassionate use applications. Encouraged by promising preclinical data, SMSbiotech is also investigating applications in orthopaedics and other therapeutic areas.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
